E
Ena Wang
Researcher at Qatar Airways
Publications - 308
Citations - 23946
Ena Wang is an academic researcher from Qatar Airways. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 74, co-authored 306 publications receiving 21485 citations. Previous affiliations of Ena Wang include Society for Immunotherapy of Cancer & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Molecular classification of cutaneous malignant melanoma by gene expression profiling
M. Bittner,Paul S. Meltzer,Yi Chen,Yong-hui Jiang,E. A. Seftor,Mary J.C. Hendrix,Michael D. Radmacher,Richard M. Simon,Zohar Yakhini,Amir Ben-Dor,Amir Ben-Dor,Nick Sampas,Edward R. Dougherty,Ena Wang,Francesco M. Marincola,C. Gooden,John Lueders,Arthur A. Glatfelter,P.C.A. Pollock,John D. Carpten,E. Gillanders,D. Leja,K. Dietrich,Christian Beaudry,Michael E. Berens,David S. Alberts,Vernon K. Sondak,Nicholas K. Hayward,J.M. Trent +28 more
TL;DR: Many genes underlying the classification of this subset of melanomas are differentially regulated in invasive melanomas that form primitive tubular networks in vitro, a feature of some highly aggressive metastatic melanomas.
Journal ArticleDOI
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida,Amiran Dzutsev,C. Andrew Stewart,Loretta Smith,Nicolas Bouladoux,Rebecca A. Weingarten,Daniel A. Molina,Rosalba Salcedo,Timothy C. Back,Sarah D. Cramer,Ren-Ming Dai,Hiu Kiu,Marco Cardone,Shruti Naik,Anil K. Patri,Ena Wang,Francesco M. Marincola,Francesco M. Marincola,Karen M. Frank,Yasmine Belkaid,Giorgio Trinchieri,Romina S. Goldszmid +21 more
TL;DR: Optimal responses to cancer therapy require an intact commensal microbiota that mediates its effects by modulating myeloid-derived cell functions in the tumor microenvironment, and disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy.
Journal ArticleDOI
A human memory T cell subset with stem cell-like properties
Luca Gattinoni,Enrico Lugli,Yun Ji,Zoltan Pos,Chrystal M. Paulos,Máire F. Quigley,Máire F. Quigley,Jorge R. Almeida,Emma Gostick,Zhiya Yu,Carmine Carpenito,Ena Wang,Daniel C. Douek,David Price,David Price,Carl H. June,Francesco M. Marincola,Mario Roederer,Nicholas P. Restifo +18 more
TL;DR: A long-lived human memory T cell population that has an enhanced capacity for self-renewal and a multipotent ability to derive central memory, effector memory and effector T cells is described.
Journal ArticleDOI
High-fidelity mRNA amplification for gene profiling.
TL;DR: A procedure that optimizes amplification of low-abundance RNA samples by combining antisense RNA (aRNA) amplification with a template-switching effect is devised, and the fidelity of aRNA amplified was comparable to expression profiles observed with conventional poly(A) RNA- or T-RNA-based arrays.
Journal ArticleDOI
Cancer classification using the Immunoscore: a worldwide task force
Jérôme Galon,Franck Pagès,Francesco M. Marincola,Francesco M. Marincola,Helen K. Angell,Helen K. Angell,Magdalena Thurin,Alessandro Lugli,Inti Zlobec,Anne Berger,Carlo Bifulco,Gerardo Botti,Fabiana Tatangelo,Cedrik M. Britten,Sebastian Kreiter,Lotfi Chouchane,Paolo Delrio,Hartmann Arndt,Martin Asslaber,Michele Maio,Giuseppe Masucci,Martin C. Mihm,Fernando Vidal-Vanaclocha,James P. Allison,Sacha Gnjatic,Leif Håkansson,Christoph Huber,Harpreet Singh-Jasuja,Christian H. Ottensmeier,Heinz Zwierzina,Luigi Laghi,Fabio Grizzi,Pamela S. Ohashi,Patricia Shaw,Blaise Clarke,Bradly G. Wouters,Yutaka Kawakami,Shoichi Hazama,Kiyotaka Okuno,Ena Wang,Jill O'Donnell-Tormey,Christine Lagorce,Graham Pawelec,Michael I. Nishimura,Robert E. Hawkins,Réjean Lapointe,Andreas Lundqvist,Samir N. Khleif,Shuji Ogino,Peter Gibbs,Paul Waring,Noriyuki Sato,Toshihiko Torigoe,Kyogo Itoh,P. Patel,Shilin N. Shukla,Richard Palmqvist,Iris D. Nagtegaal,Yili Wang,Corrado D'Arrigo,Scott Kopetz,Frank A. Sinicrope,Giorgio Trinchieri,Thomas F. Gajewski,Thomas F. Gajewski,Paolo A. Ascierto,Bernard A. Fox,Bernard A. Fox,Bernard A. Fox +68 more
TL;DR: Evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy, into traditional classification of cancer, designated TNM-I (TNM-Immune), and introduction of this parameter as a biomarker to classify cancers will facilitate clinical decision-making.